Login to Your Account



PDL Regains Roche's Zenapax Rights In Non-Transplantation

By Karen Pihl-Carey


Wednesday, October 1, 2003
With the intention of developing the approved drug Zenapax in other indications, Protein Design Labs Inc. restructured its commercial deal with Hoffmann-La Roche Inc. regaining exclusive worldwide rights in all indications other than organ transplantation. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription